Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Goto

Showing results (121-130 of 265) with videos related to

Pageof 27
Sort By:
International Journal of Cardiology|August 27, 2021
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registryFabien Picard, Deepak L Bhatt, Grégory Ducrocq, et al.
Atherosclerosis|December 5, 2008
Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) RegistryPatrice P Cacoub, Maria Teresa B Abola, Iris Baumgartner, et al.
Stroke|February 12, 2013
Efficacy and safety of vorapaxar in patients with prior ischemic strokeDavid A Morrow, Mark J Alberts, Jay P Mohr, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|February 23, 2010
Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACEHiroshi Inoue, Takashi Nozawa, Tadakazu Hirai, et al.
Frontiers in Veterinary Science|December 21, 2020
The Suppression of Th1 Response by Inducing TGF-β1 From Regulatory T Cells in Bovine MycoplasmosisYamato Sajiki, Satoru Konnai, Shinya Goto, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|February 28, 2012
One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event REduction after STroke) registryNorihiro Suzuki, Motoki Sato, Kiyohiro Houkin, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|April 8, 2014
Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to ageMasatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 20, 2013
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trialMasatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|November 6, 2013
Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AFShinichiro Uchiyama, Masatsugu Hori, Masayasu Matsumoto, et al.
International Journal of Cardiology|May 8, 2012
Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortalityRonan Roussel, Samy Hadjadj, Blandine Pasquet, et al.
Pageof 27

Showing results (121-130 of 265) with videos related to

Sort By:
Pageof 27
International Journal of Cardiology|August 27, 2021
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registryFabien Picard, Deepak L Bhatt, Grégory Ducrocq, et al.
Atherosclerosis|December 5, 2008
Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) RegistryPatrice P Cacoub, Maria Teresa B Abola, Iris Baumgartner, et al.
Stroke|February 12, 2013
Efficacy and safety of vorapaxar in patients with prior ischemic strokeDavid A Morrow, Mark J Alberts, Jay P Mohr, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|February 23, 2010
Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACEHiroshi Inoue, Takashi Nozawa, Tadakazu Hirai, et al.
Frontiers in Veterinary Science|December 21, 2020
The Suppression of Th1 Response by Inducing TGF-β1 From Regulatory T Cells in Bovine MycoplasmosisYamato Sajiki, Satoru Konnai, Shinya Goto, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|February 28, 2012
One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event REduction after STroke) registryNorihiro Suzuki, Motoki Sato, Kiyohiro Houkin, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|April 8, 2014
Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to ageMasatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 20, 2013
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trialMasatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|November 6, 2013
Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AFShinichiro Uchiyama, Masatsugu Hori, Masayasu Matsumoto, et al.
International Journal of Cardiology|May 8, 2012
Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortalityRonan Roussel, Samy Hadjadj, Blandine Pasquet, et al.
Pageof 27